Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 5,349 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Terminated Phase 3 Interventional Results available

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

NCT00740714
View directory record Official record
Conditions
Parkinson Disease
Interventions
Coenzyme Q10 with vitamin E, placebo with vitamin E
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 25, 2026, 8:09 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

NCT01088984
View directory record Official record
Conditions
Leukemia
Interventions
Bendamustine
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Year to 20 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Orange, California • San Diego, California • St. Petersburg, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo tablets, Riluzole
Drug · Other
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 4 Interventional

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
52
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 25, 2026, 8:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Self-sampling to Optimize Anal Lesion Outcomes

NCT07192055
View directory record Official record
Conditions
Anal Cancer
Interventions
Self-sampling, Nylon-flocked Swab
Behavioral · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
35 Years and older
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Terminated Phase 2 Interventional Results available

Belatacept in Liver Transplant Recipients

NCT00555321
View directory record Official record
Conditions
Immunosuppression in Solid Organ Transplant
Interventions
Tacrolimus, Basiliximab, Belatacept More Intensive (MI), Belatacept Less Intensive (LI), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 25, 2026, 8:09 PM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Withdrawn No phase listed Observational

Diagnosing Malfunctioning Hydrocephalic Shunt Valves With a Flow Sensor

NCT00652249
View directory record Official record
Conditions
Hydrocephalus
Interventions
Not listed
Lead sponsor
Transonic Systems Inc.
Industry
Eligibility
Up to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 25, 2026, 8:09 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

High Volume Lactated Ringer's Solution and Pancreatitis

NCT02050048
View directory record Official record
Conditions
Pancreatitis
Interventions
Administration of Lactated Ringer's (LR) Solution
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Evanston, Illinois • Highland Park, Illinois • Skokie, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 25, 2026, 8:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

NCT03728348
View directory record Official record
Conditions
Colorectal Cancer
Interventions
mt-sDNA screening test, Colonoscopy
Diagnostic Test · Procedure
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
45 Years to 49 Years
Enrollment
983 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Camarillo, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

NCT00300755
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole sodium enteric-coated spheroid
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Year to 5 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1226
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Terminated No phase listed Observational

Predictive Assay for Decision Making in Adjuvant Therapy

NCT05032352
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Adjuvant, Observation
Drug · Other
Lead sponsor
Insight Molecular Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
18
States / cities
Duarte, California • Washington D.C., District of Columbia • Jupiter, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging
Radiation · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
678
States / cities
Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder

NCT01655485
View directory record Official record
Conditions
Anxiety
Interventions
Patient teaching
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 16 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 25, 2026, 8:09 PM EDT
Recruiting Not applicable Interventional

Use of Sensory Substitution to Improve Arm Control After Stroke

NCT03298243
View directory record Official record
Conditions
Stroke, Proprioceptive Disorders
Interventions
Vibrotactile stimulation
Behavioral
Lead sponsor
Marquette University
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

NCT05084638
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 8:09 PM EDT
Terminated Phase 2 Interventional Results available

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047
View directory record Official record
Conditions
AL Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Duarte, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 2 Interventional

Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

NCT00141349
View directory record Official record
Conditions
Impotence
Interventions
UK-369,003
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
39
States / cities
Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2006 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 3 Interventional

Effect of Growth Hormone in Children With Growth Hormone Deficiency

NCT00262249
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children, Growth Disorder, Idiopathic Short Stature
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
40
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT01683838
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 25, 2026, 8:09 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

NCT03219476
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 8:09 PM EDT